Squarepoint
DMRA

Squarepoint’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Squarepoint’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$608K Buy
+23,458
New +$603K ﹤0.01% 3179
2025
Q2 		– Sell
-12,984
Closed -$40.3K – 4692
2025
Q1 		$40.3K Buy
12,984
+283
+2% +$1.33K ﹤0.01% 4377
2024
Q4 		$59.1K Buy
+12,701
New +$83.1K ﹤0.01% 4812

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Squarepoint's DMRA Position: Q1 2026 in Review

Squarepoint opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 23,458 shares worth $608K. The stake represents ﹤0.01% of the portfolio and ranks #3179 among its holdings. This is a return to the name: Squarepoint previously reported a position in DMRA as recently as Q1 2025.

Squarepoint first reported a position in DMRA in Q4 2024 and has held it in 3 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Squarepoint held 23,458 shares of Damora Therapeutics, Inc. Ordinary Shares worth $608K as of Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares was a new Squarepoint position in Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3179 holding.
  • Squarepoint first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2024 and has held it in 3 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.